Novo Nordisk has announced an investment of more than DNK 42 billion ($6.1 billion) starting in 2023 to expand existing manufacturing facilities in Kalundborg, Denmark, for the company’s current and future product portfolio within chronic diseases. 

The investment will create additional capacity across the value chain from manufacturing of active pharmaceutical ingredients (APIs) to packaging, with the vast majority invested in API capacity. The new API facility will be designed as a multi-product facility, with flexibility to accommodate current and future processes. The facility will have a footprint of 170,000 m².  

The construction projects will be finalized gradually from the end of 2025 through 2029. The projects are expected to create 800 new jobs in the facilities when construction is completed, and the facilities are fully equipped. 

Source: Novo Nordisk